Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

Researchers developed the first human antibody cocktail to completely protect against the lethal Nipah and Hendra virus infection in preclinical models.

AI‑guided analysis surfaces a new CAR T target with multi‑cancer activity, as Penn researchers validate GPNMB‑directed CAR T cells in preclinical models.

The discussion covered plans to increase the agency's headcount and to expedite early through late-stage clinical development in the U.S.

This GEN Live show will bring together a panel of leading experts to break down the latest advances, innovations, and challenges shaping genome editing.

Discoveries may help to explain why some bacteria are hard to eliminate, and also point to potential future approaches to improving antibiotic effectiveness.

Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...

InduPro will combine its proprietary bispecific antibody capabilities with Lonza’s antibody–drug conjugate platform.

For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.

California’s three life sciences clusters all lost jobs last year, yet the industry remains a major engine of innovation and economic growth, according to a report released by the state’s largest life ...

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...